David Gill

David Gill

Directeur/Membre du Conseil chez EVOLUS, INC.

Fortune : 271 112 $ au 31/05/2026

71 ans
Health Technology
Technology Services
Health Services

Profil

David Neil Gill is currently Independent Director at Evolus, Inc. since 2018; Director at The Alfred E.
Mann Foundation For Scientific Research, Bioretec Ltd. starting 2026, Bridge to Life Ltd., Allucent LLC, and RapidPulse, Inc.; Independent Non-Executive Director at Telix Pharmaceuticals Ltd. starting 2026; and Chief Financial Officer at Perspectum Group Ltd. since 2021.
Former roles include Chairman at Melinta Therapeutics, Inc. from 2019 to 2020; Independent Director at STRATA Skin Sciences, Inc. from 2018 to 2020; Independent Director at Histogenics Corp.
from 2015 to 2019; Independent Director at Cempra, Inc. from 2012 to 2020; Independent Director at Strongbridge Biopharma Plc from 2019 to 2021; Independent Director at Y-mAbs Therapeutics, Inc. from 2017 to 2025; Director at LeMaitre Vascular, Inc. from 2006 to 2008; Director at IsoTis OrthoBiologics, Inc. from 2006 to 2009; Chief Operating Officer at Novoste Corp.
from 1996 to 2000; President & Chief Operating Officer at Interland, Inc. from 2000 to 2001; Chief Financial Officer & Senior Vice President at CTI Molecular Imaging, Inc. from 2002 to 2005; President, Chief Operating & Financial Officer at EndoChoice, Inc. in 2016; Chief Financial Officer at TransEnterix, Inc. from 2009 to 2011; Chief Financial Officer at Syneos Health NC LLC from 2011 to 2013; Chief Financial Officer & Treasurer at NxStage Medical, Inc. from 2005 to 2006; Chief Financial Officer at INC Research Holdings, Inc. from 2011 to 2013; Chief Financial Officer at Perspectum Ltd. in 2021; Director at Calypso Medical Technologies, Inc. from 2000 to 2012; and Director at several other companies including IdleAire Technologies Corp., Cempra Pharmaceuticals, Inc., Novum Medical, Inc., EOS Imaging SA, and Azanta A. Education includes undergraduate studies at Wake Forest University and an MBA from Emory University.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
17/04/2026 41 328 ( 0,06 % ) 271 112 $ 31/05/2026

Postes actifs de David Gill

SociétésPosteDébut
BIORETEC OY Directeur/Membre du Conseil 08/05/2026
TELIX PHARMACEUTICALS LIMITED Directeur/Membre du Conseil 11/05/2026
EVOLUS, INC. Directeur/Membre du Conseil 12/02/2018
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
Directeur Financier/CFO 09/07/2021
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -

Anciens postes connus de David Gill

SociétésPosteFin
YMAS THER Directeur/Membre du Conseil 16/09/2025
░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de David Gill

Formation de David Gill

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

60

Relations au 1er degré

36

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées36

Health Technology

Technology Services

Health Technology

Health Technology

Health Technology

Producer Manufacturing

Health Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Commercial Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Miscellaneous

Dornier Medical Systems, Inc.

Health Technology

Health Technology

Health Technology

Commercial Services

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

  1. Bourse
  2. Insiders
  3. David Gill
- 40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT
🔇